Optos Unveils MonacoPro: The Next Generation in Integrated Ultra-widefield and OCT Retinal Imaging
Dunfermline, UK – 14 February 2025 – Optos PLC, a pioneer and leader in retinal imaging technology, announces the launch of MonacoPro, the next-generation ultra-widefield (UWF™) SLO and spectral domain retinal imaging solution. Building on the legacy of Monaco®, MonacoPro introduces features designed to elevate diagnostic precision and streamline workflow for eyecare professionals worldwide.
“MonacoPro represents our commitment to continuous innovation in ophthalmic imaging,” said Optos Chief Executive Officer Robert Kennedy. “With new advancements in automation, and data analysis, we are empowering clinicians with tools that enhance efficiency and diagnostic confidence while maintaining our industry-leading ultra-widefield imaging capabilities.”
Key Product Features:
MonacoPro OCT Image Quality for Demanding Practices
New MonacoPro OCT image quality provides highly detailed and precise retinal images that meet the needs of even the most demanding eyecare practices. With MonacoPro, practitioners can visualize and analyze retinal layers with greater accuracy, supporting diagnosis and treatment planning. When combined with the integrated 200° single-shot optomap imaging, MonacoPro increases the identification of macular pathology when compared with fundus imaging alone by 29.4%.1
AreaAssist: Streamlined Efficiency for Enhanced Workflow
MonacoPro also marks the introduction of the new AreaAssist tool, designed to improve the efficiency of retinal imaging workflows. AreaAssist enables users to automatically measure continuous areas of matching color and adjust the sensitivity of the selected area with a simple “click and drag” of the mouse. By automating and simplifying these processes, AreaAssist removes the need for time-consuming manual tasks, allowing practitioners to focus on patient care and clinical decision-making.
One of the Largest Reference Databases in Retinal Imaging
The Optos Reference Database in the US market, on the MonacoPro now includes 879 eyes and stratifies based on different optic disc sizes in addition to age. Research has demonstrated that normalizing reference data by ONH size is a more effective approach than other criteria for identifying relevant population data, leading to greater diagnostic precision.2
Optos remains dedicated to advancing retinal imaging technology to support eyecare professionals in diagnosing and managing ocular pathology with greater confidence. The launch of MonacoPro underscores the ongoing investment in cutting-edge solutions that drive efficiency, enhance clinical accuracy, and improve patient outcomes.
MonacoPro will be available for shipping beginning in March 2025.
For more information about MonacoPro and industry-leading retinal imaging technology by Optos, please visit www.optos.com.
Supporting Research:
1Aiello et al.: INTEGRATING MACULAR OPTICAL COHERENCE TOMOGRAPHY WITH ULTRAWIDE-FIELD IMAGING IN A DIABETIC RETINOPATHY TELEMEDICINE PROGRAM USING A SINGLE DEVICE. Retina 2023 Nov 1;43(11):1928-1935.
2Salazar et al.: Optical Coherence Tomography Measurement Correlations with Age and Optic Disc Size. Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4848
- Chaglasian et al.: Accuracy of Glaucoma Detection with a Novel Imaging Device: Combined UWF-SLO and SD-OCT. Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4841
- Sinai et al. : Structure and Function Relationship in Glaucoma with a Novel Multi-Modal Imaging Device Combining UWF-SLO and SD-OCT. Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2541
About Optos
For more than 30 years, Optos has been the exclusive provider of 200-degree single-shot ultra-widefield retinal imaging systems to eye care professionals worldwide. With over 27,000 devices in use and supported by more than 3,000 clinical papers,
Optos has also developed integrated ultra-widefield retinal imaging with optomap-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. Optos continues to lead the way in retinal imaging technology, setting the standard for excellence and innovation in eye care.
Media Contact:
Cassy Dump
Shine Communications for Optos
(619) 971-1887
Organization Contact:
Sharon Shepard